Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR

Vaccine

Volumn 28, Issue 3, 2010, Pages 692-698

  Diaz Ortega, Jose Luis ^a   Bennett, John V ^b   Castaneda, Deyanira ^a   Vieyra, Jose Raul ^a   Valdespino Gomez, Jose Luis ^c   Fernandez de Castro, Jorge ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Birmex   (Mexico)

Author keywords

Aerosol; Measles; Mumps; Rubella; Safety; Seroresponses; Vaccines

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADULT; AEROSOL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG FEVER; DRUG RESPONSE; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RUBELLA; VIRUS STRAIN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; ANTIBODIES, VIRAL; FEMALE; HUMANS; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; RUBELLA; YOUNG ADULT;

EID: 71549121031     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.083     Document Type: Article

References (43)

1. CDC. Progress in reducing measles mortality-worldwide, 1999-2003. Morb Mortal Wkly Rep 54 (2005) 200-203
2. CDC. Progress toward measles elimination-region of the Americas, 2002-2003. Morb Mortal Wkly Rep 53 (2004) 304-306
3. de Quadros C.A., Izurieta H., Venczel L., and Carrasco P. Measles eradication in the Americas: progress to date. J Infect Dis 189 Suppl. 1 (2004) S227-S235
4. Izurieta H., Venczel L., Dietz V., Tambini G., Barrezueta O., Carrasco P., et al. Monitoring measles eradication in the region of the Americas: critical activities and tools. J Infect Dis 187 Suppl. 1 (2003) S133-S139
5. WHO. Progress towards measles elimination, western hemisphere, 2002-2003. Wkly Epidemiol Rec 15 (2004) 149-151
6. Parker A.A., Staggs W., Dayan G.H., Ortega-Sanchez I.R., Rota P.A., Lowe L., et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 355 (2006) 447-455
7. SSA. Dirección General de Epidemiología. http://www.epi.org.mx/.
8. De-Quadros C., Olivé J.M., Hersh B.S., Strassburg M.A., Henderson D.A., Branding-Bennett D., et al. Measles elimination in the Americas. Evolving strategies. J Am Med Assoc 275 (1996) 224-229
9. Sabin A.B., Flores A.A., Fernández de Castro J., Sever J.L., Madden D.L., Shekarchi I., et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. J Am Med Assoc 249 (1983) 2651-2662
10. Sabin A.B., Flores A.A., Fernández de Castro J., Sever J.L., Madden D.L., Shekarchi I., et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. J Am Med Assoc 251 (1984) 2363-2371
11. Fernández de Castro J., Valdespino G.J.L., Díaz-Ortega J.L., and Zárate A.M.L. Diploid cell measles vaccine. J Am Med Assoc 256 (1986) 714
12. Fernández de Castro J., and Kumate J. La vacunación contra el sarampión. Situación en México y América. Avances en el método de inmunización por aerosol. Bol Med Hosp Infant Mex 47 (1990) 449-546
13. Bellanti J.A., Zeligs B.J., Medez-Inocencio J., Garcia-Garcia M.L., Islas-Romero R., Omidvar B., et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 22 (2004) 1214-1220
14. Cutts F., Clements C.J., and Bennett J.V. Alternative routes of measles immunization: a review. Biologicals 25 (1997) 323-338
15. Fernández Bracho J.G., and Roldán Fernández S. Reacciones tempranas en escolares vacunados con antisarampionosa en aerosol. Salud Pública Mex 32 (1990) 653-657
16. Sepúlveda-Amor J., Valdespino-Gómez J.L., García-García M.L., Bennett J., Islas-Romero R., Echaniz-Aviles G., et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 20 (2002) 2790-2795
17. Bennett J.V., Fernández de Castro J., Valdespino J.L., García-García M.L., Islas-Romero R., Echaniz G., et al. Aerosols of measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican school children. Bull WHO 80 (2002) 806-812
18. Dilraj A., Cutts F.T., Fernandez de Castro J., Wheeler J.G., Brown D., Roth C., et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial. Lancet 355 (2000) 798-803
19. Dilraj A., Cutts F.T., Bennett J.V., Fernandez de Castro J., Cohen B., and Coovadia H.M. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous route. Pediatr Infect Dis J 19 (2000) 1211-1213
20. Dilraj A., Sukhoo R., Cutts F.T., and Bennett J.V. Aerosol and subcutaneous measles vaccine: antibody responses 6 years after re-vaccination. Vaccine 25 (2007) 4170-4174
21. Wong-Chew R.M., Islas-Romero R., García-García M.L., Beeler J.A., Audet S., Santos-Preciado J.I., et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 189 (2004) 254-257
22. Wong-Chew R.M., Islas-Romero R., García-García M.L., Beeler J.A., Audet S., Santos-Preciado J.I., et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 24 (2006) 683-690
23. Hosai H., Yamanishi K., Ueda S., Minekawa Y., and Ogino T. Studies of live attenuated mumps virus vaccine. 1. Attenuation of mumps virus by serial passage in the chorioallantoic cavity of developing chick embryos and field trials by the inhalation method. Biken J 13 (1970) 121-126
24. Fernandez de Castro J., Bennett J.V., Gallardo Rincon H., Alvarez y Muñoz M.T., Partida Sanchez L.A.E., and Santos J.I. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine 23 (2005) 1079-1084
25. Bennett J.V., Fernandez de Castro J., Martinez Poblete R., Garcia Alcantara M.L., Galardo Diaz E., Molina Angeles M.A., et al. A new, rapid and promising approach to aerosol immunization: inflatable bags and valved masks. Vaccine 27 (2009) 4571-4575
26. Tischer A., and Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, and rubella. Vaccine 18 14 (2000) 1382-1392
27. Cruz Rojo C., Rodriquez Iglesias M., Olvera J., and Alvarez Giron M. Study of the immune response engendered by different combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 22 2 (2003) 280-286
28. Global status of mumps immunization and surveillance. Wkly Epidemiol Rec 80 #48 (2005) 418-424
29. Parks C.L., Lerch R.A., Walpita P., Wang H.P., Sidhu M.S., and Udem S.A. Comparison of predicted amino acid sequences of measles virus strains in the Edmonston lineage. J Virol 75 2 (2001) 910-920
30. Chen R.T., Markowitz L., Albrecht P., Stewrt J.A., Mofenson L.M., Preblud S.R., et al. Measles antibody: reevaluation of protective titers. JID 162 (1990) 1036-1042
31. Cohen B.J., Audet S., Andrews N., and Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardized laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 26 (2007) 59-66
32. Abbott Laboratories. Abbott Axsym System Rubella IgG. Instruction booklet (2002)
33. Institute Virion/Serion GmbH. Serion ELISA classic Parotitis Virus IgG. Instruction manual; 2004.
34. Horne A.D., Lachenbrush P.A., Getson P.R., and Hsu H.S. Analysis of studies to evaluate immune response to combination vaccines. Clin Infect Dis 33 Suppl. 4 (2001) S306-S311
35. Agreste A. An introduction to categorical data analysis. Wiley Series in Probability and Statistics (1996), Wiley-Interscience, U.S.A.
36. Low N., Kraemer S., Schneider M., and Henao-Restrepo A.M. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 26 (2008) 383-398
37. Richard J.L., Zwahlen M., Feuz M., and Matter H.C. Swiss sentinel surveillance network. Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: a case cohort study. Eur J Epidemiol 18 (2003) 569-577
38. Peltola H., Kulkarni P.S., Kapre S.V., Punio M., Jadhov S.S., and Dhere R.M. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis 45 (2007) 459-466
39. Dayan G.H., and Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis 47 (2008) 1458-1467
40. Diaz-Ortega J.L., Meneses-Reyes C.D., and Palacios-Martinez M. Incidencia y patrones de transmisión de rubeola en México. Salud Publica Mex 49 (2007) 337-344
41. Wilkins J., Leedor J.M., Salvatore M.A., and Portnoy B. Transmission of rubella vaccine virus from vaccinees to contacts. Calif Med 115 (1971) 16-22
42. Ruiz-Gomez J., Gutierrez G., and Velasco-Candano L.R. Evaluación de la vacuna contra rubéola (HPV 77, DK12) en la ciudad de México. Posible transmisión de la cepa vacunal. Arch Invest Med (Mex) 2 (1971) 95-102
43. Schiff G.M., and Bloom J.E. Evaluation of rubella vaccination in a large school system. J Pediatr 78 (1971) 211-219